

Significant Publications

1. Atkins H, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny H, Hamelin L, Huebsch L, Hutton B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O'Connor P, Ramsay T, Sabloff M, Walker L, and **MS Freedman**. Immunoablation and Autologous Hematopoietic Stem Cell Rescue Arrests All Measurable Inflammatory Activity and Facilitates Lasting Recovery in Aggressive Multiple Sclerosis. The Lancet 2016 Aug 6;388(10044):576-85.
2. Rush CA, MacLean HJ, **Freedman MS**. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015 Jul;11(7):379-89
3. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Cadavid D, Cohen JA, **Freedman MS**, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D. Mult Scler. **2016** Mar 22
4. ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis. Khoury SJ, Rochon J, Ding L, Byron M, Ryker K, Tosta P, Gao W, **Freedman MS**, Arnold DL, Sayre PH, Smilek DE; ACCLAIM Study Group. Mult Scler. **2016** Aug 1
5. Menon S, Zhu F, Shirani A, Oger J, **Freedman MS**, Tremlett H. Disability progression in aggressive multiple sclerosis. Mult Scler. **2016** Jun 20
6. Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. Lee H, Narayanan S, Brown RA, Chen JT, Atkins HL, **Freedman MS**, Arnold DL. Mult Scler. 2016 June; 1-12.
7. Cadavid D, Cohen JA, **Freedman MS**, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2016 Mar
8. MacMillan EL, Tam R, Zhao Y, Vavasour IM, Li D, Oger J, **Freedman MS**, Kolind SH, Traboulsee AL. Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years. Mult Scler. 2016;22(1):112-6.
9. Kappos L, De Stefano N, **Freedman MS**, Cree BA, Radue EW, Sprenger T, Sormani MP, Smith T, Häring DA, Piani Meier D, Tomic D. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2015 Nov
10. MacMillan EL, R Tam, Y Zhao, IM Vavasour, DKB Li, J Oger, **MS Freedman**, SH Kolind and AL Traboulsee. Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years. Mult Sclerosis Journal. 2015 May